Pharmaceuticals, Biotechnology and Life Sciences
Novo Nordisk’a new results from the STEP phase 3a clinical trial programme showed weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4 mg versus placebo.
PureTech Health’s affiliate Gelesis has rasied $30 million to back bringing closer to shelves its pipeline of additinoal gastrointestinal disorders product candidates,…
The study “Mechanisms, Pathophysiology, and Management of Obesity” underscores the key elements of treating obesity which include live counseling, a low-calorie diet, physical activity and behavior modification – all of which are fundamental elements of the weight loss program.
Gelesis, focused on developing first-in-class products to safely induce weight loss and improve glycaemic control, has presented new data for its second product candidate, Gelesis200
The Food and Drug Administration (FDA) revealed Thursday latest products it had found containing hidden drug ingredients.
The Food and Drug Administration (FDA) is advising consumers not to purchase or use NATUREAL, a product promoted and sold for weight loss.